Stocks and Investing
Stocks and Investing
Thu, November 17, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, November 16, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Robyn Karnauskas Initiated (ABCL) at Strong Buy and Held Target at $29 on, Nov 16th, 2022
Robyn Karnauskas of Truist Securities, Initiated "AbCellera Biologics Inc." (ABCL) at Strong Buy and Held Target at $29 on, Nov 16th, 2022.
Robyn has made no other calls on ABCL in the last 4 months.
There are 3 other peers that have a rating on ABCL. Out of the 3 peers that are also analyzing ABCL, 0 agree with Robyn's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Robyn
- Puneet Souda of "SVB Leerink" Maintained at Buy with Increased Target to $20 on, Wednesday, November 9th, 2022
- Tiago Fauth of "Credit Suisse" Maintained at Buy with Decreased Target to $34 on, Wednesday, August 10th, 2022
- Do Kim of "Piper Sandler" Maintained at Buy with Increased Target to $22 on, Tuesday, July 26th, 2022
Contributing Sources